Table 2.
Clinical trials evaluating intravitreal corticosteroids for macular edema due to BRVO.
| Study | Author/year | Method | Duration | Subjects | Mean BCVA change | Mean CMT change (μm) | Number of injections |
|---|---|---|---|---|---|---|---|
| ORVO | Campochiaro et al. 2015 | Dexamethasone 0.7 mg (all patients have treated with anti-VIGF agents before) |
16 weeks | 17 | 4 weeks: ~+5.8 (ETDRS) 16 weeks: ~+5.8 (Peak at 4 weeks) |
4 weeks: ~−153 16 weeks: ~−60 (Peak at 4 weeks) |
1 |
|
| |||||||
| SHASTA | Capone et al. [150] | Dexamethasone 0.7 mg | 1.2 years | 157 | ~+5.0 (ETDRS) | −154~−188 | 3.2 |
|
| |||||||
| SOLO | Bezatis et al. [152] | Dexamethasone 0.7 mg | 6 months | 54 | 8 weeks: +0.3 (LogMAR) 24 weeks: +0.15 (Peak at 8 weeks) |
8 weeks: −214 24 weeks: −107 (Peak at 8 weeks) |
1.3 |
|
| |||||||
| GENEVA | Haller et al. [146] | Dexamethasone 0.35 mg/0.7 mg | 208 | 60 days: ~+10.2 (ETDRS) 180 days: ~+6.1 |
180 days: −103 360 days: −163 |
1.85 | |
| Dexamethasone 0.7 mg/0.7 mg | 12 months | 227 | 60 days: ~+10.1 180 days: ~+6.2 360 days: ~+6.3 |
180 days: −97 360 days: −166 |
1.86 | ||
| Sham/0.7 mg (0–6 months/6–12 months) | 210 | 60 days: ~+4.7 180 days: ~+3.8 360 days: ~+6.1 (Peak at 60 days) |
180 days: −102 360 days: −170 |
0.83 | |||
|
| |||||||
| SCORE | Ingrid et al. 2009 | Triamcinolone 1 mg Triamcinolone 4 mg Standard care |
12 months | 136 137 137 |
+5.7 (ETDRS) +4 +4.2 |
−245 −250 −312 |
2.2 2.1 N/A |
Note: only BRVO patients are analyzed in this table. Outcomes are not directly comparable because study design and populations varied from each other. Some studies did not report the accurate number and are estimated by the figures. BRVO: branch retinal vein occlusion; BCVA: best-corrected visual acuity; CMT: central macular thickness; ETDRS: early treatment diabetic retinopathy study; LogMAR: logarithm of the minimum angle of resolution; ORVO: the Ozurdex for retinal vein occlusion study: SHASTA: efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion; SOLO: functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion; GENEVA: sham-controlled randomized trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion; SCORE: the standard care versus corticosteroid for retinal vein occlusion trial.